World Journal of Case Reports and Clinical Images
The first patient-derived stem cell model to research eye conditions
related to oculocutaneous albinism (OCA) has been created.
Researchers at the US National Eye Institute (NEI) have developed the
first patient-derived stem cell model for studying eye conditions related to
oculocutaneous albinism (OCA).
According to the researchers, OCA is a
set of genetic conditions that affects pigmentation in the eye, skin and hair
due to mutation in the genes crucial to melanin pigment production. In the eye,
pigment is present in the retinal pigment epithelium (RPE) and aids vision by
preventing the scattering of light. The RPE is located right next to the eyes
light-sensing photoreceptors and provides them nourishment and support. People
with OCA lack pigmented RPE and have an underdeveloped fovea, an area within
the retina that is crucial for central vision.
People with OCA have misrouted optic
nerve fibres, which carry visual signals to the brain. Scientists think that
RPE plays a role in forming these structures and want to understand how lack of
pigment affects their development.
Animals used to study albinism are less
than ideal because they lack foveae, said Dr Brian Brooks, one of the authors
of the paper published in Stem Cell Reports. A human stem cell model that
mimics the disease is an important step forward in understanding albinism and
testing potential therapies to treat it.
To make the model, the researchers
reprogrammed skin cells from individuals without OCA and people with the two
most common types of OCA (OCA1A and OCA2) into induced pluripotent stem cells
(iPSCs). The iPSCs were then differentiated to RPE cells. The RPE cells from
OCA patients were identical to RPE cells from unaffected individuals but
displayed significantly reduced pigmentation.
The researchers say they will use the
model to study how lack of pigmentation affects RPE physiology and function. In
theory, if fovea development is dependent on RPE pigmentation and pigmentation
can be somehow improved, vision defects associated with abnormal fovea
development could be at least partially resolved.
Treating albinism at a very young age,
perhaps even prenatally, when the eyes structures are forming, would have the
greatest chance of rescuing vision, said Brooks. In adults, benefits might be limited to improvements in
photosensitivity, for example, but children may see more dramatic effects.
The team say they are now exploring how
to use their model for high-throughput screening of potential OCA therapies.
This disease-in-a-dish system will help us understand how the absence of pigment in albinism leads to abnormal development of the retina, optic nerve fibres and other eye structures crucial for central vision, said Dr Aman George, the lead author of the paper.